Core Insights - Moleculin Biotech, Inc. has announced that its abstract has been accepted for poster presentation at the Acute Leukemias XIX International Symposium, scheduled for March 16-19, 2025, in Munich, Germany [1][2]. Company Overview - Moleculin Biotech, Inc. is a late-stage pharmaceutical company focused on developing drug candidates for hard-to-treat tumors and viruses. Its lead program, Annamycin, is a next-generation anthracycline aimed at overcoming multidrug resistance and reducing cardiotoxicity associated with traditional anthracyclines [3]. - The company is currently advancing a pipeline that includes Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases [3]. Clinical Trials - The company is initiating the MIRACLE Trial (MB-108), a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory AML. This follows a successful Phase 1B/2 study, which has provided confidence in the development pathway towards potential approval [4]. - The trial design is adaptive, and the company is preparing for future regulatory filings with the FDA and other international regulatory bodies [4]. Additional Developments - Moleculin is also developing WP1066, an immune/transcription modulator targeting various cancers, including brain tumors and pancreatic cancer. Additionally, the company is working on a portfolio of antimetabolites, including WP1122, aimed at treating pathogenic viruses and certain cancer indications [5].
Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium